Abstract:Allergen-specific immunotherapy (AIT) constitutes the only curative approach for allergy treatment. There is need for improvement of AIT in veterinary medicine, such as in horses suffering from insect bite hypersensitivity, an IgE-mediated dermatitis to Culicoides. Dendritic cell (DC)-targeting represents an efficient method to increase antigen immunogenicity. It is studied primarily for its use in improvement of cancer therapy and vaccines, but may also be useful for improving AIT efficacy. Immunomodulators, like the Toll-like receptor 4 (TLR-4) agonist monophosphoryl lipid-A (MPLA) has been shown to enhance the IL-10 response in horses, while CpG-rich oligonucleotides (CpG-ODN), acting as TLR-9 agonists, have been shown to induce Th1 or regulatory responses in horses with equine asthma. Our aim was to evaluate in vitro effects of antigen-targeting to equine DC with an antigen-fused peptide known to target human and mouse DC and investigate whether addition of MPLA or CpG-ODN would further improve the induced immune response with regard to finding optimal conditions for equine AIT. For this purpose, DC-binding peptides were fused to the model antigen ovalbumin (OVA) and to the recombinant Culicoides allergen Cul o3. Effects of DC-binding peptides on cellular antigen uptake and induction of T cell proliferation were assessed. Polarity of the immune response was analysed by quantifying IFN-γ, IL-4, IL-10, IL-17 and IFN-α in supernatants of antigen-stimulated peripheral blood mononuclear cells (PBMC) in presence or absence of adjuvants. Fusion of DC-binding peptides to OVA significantly enhanced antigen-uptake by equine DC. DC primed with DC-binding peptides coupled to OVA or Cul o3 induced a significantly higher T-cell proliferation compared to the corresponding control antigens. PBMC stimulation with DC-binding peptides coupled to Cul o3 elicited a significant increase in the pro-inflammatory cytokines IFN-γ, IL-4, IL-17, as well as the anti-inflammatory IL-10, but not of IFN-α. Adjuvant addition further enhanced the effect of the DC-binding peptides by significantly increasing the production of IFN-γ, IL-4, IL-10 and IFN-α (CpG-ODN) and IL-10 (MPLA), while simultaneously suppressing IFN-γ, IL-4 and IL-17 production (MPLA). Targeting equine DC with allergens fused to DC-binding peptides enhances antigen-uptake and T-cell activation and may be useful in increasing the equine immune response against recombinant antigens. Combination of DC-binding peptide protein fusions with adjuvants is necessary to appropriately skew the resulting immune response, depending on intended use. Combination with MPLA is a promising option for improvement of AIT efficacy in horses, while combination with CpG-ODN increases the effector immune response to recombinant antigens.

Interleukin 31 in insect bite hypersensitivity—Alleviating clinical symptoms by active vaccination against itch

Active vaccination against interleukin‐5 as long‐term treatment for insect‐bite hypersensitivity in horses

Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study

IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis

Equine allergic skin diseases: Clinical consensus guidelines of the World Association for Veterinary Dermatology

Interleukin 31 in vitiligo patients with and without pruritus

Elevation of IL-2 Expressing Level in PBMC of EIAV Vaccinated Horses

IL‐4 and IL‐13 are not involved in IL‐31‐induced itch‐associated scratching behaviour in mice

An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production

Interleukin-31 Expression and Relation to Disease Severity in Human Asthma.

Influence on inflammation cytokines in passive immunotherapy for allergic rhinitis guinea pigs

Therapeutic Potential of Anti-Il-1β IgY in Guinea Pigs with Allergic Asthma Induced by Ovalbumin

Effect of intralymphatic allergen-specific immunotherapy on house dust mite in a murine model of allergic rhinitis

Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis

Divergent in situ expression of IL-31 and IL-31RA between bullous pemphigoid and pemphigus vulgaris

Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis

Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study

Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo

Therapeutic Potential of Combined Anti-Il-1β IgY and Anti-Tnf-α IgY in Guinea Pigs with Allergic Rhinitis Induced by Ovalbumin.